Why Semax Comes as a Nasal Spray

Search interest in Semax nasal spray keeps outrunning the regulatory reality behind it. The answer worth leading with is regulatory, not practical: Semax is a registered prescription medicine in Russia, sold there as a nasal spray, and it has no marketing authorization as a drug in the United States or the European Union. Everything sold outside Russia under that name is an unapproved research chemical, whatever the label claims. This explainer covers what Semax is, why the nasal route shows up in the research at all, and what that evidence base can and cannot tell a reader.

What Semax actually is

Semax is a synthetic heptapeptide, a chain of seven amino acids, built from a fragment of adrenocorticotropic hormone (ACTH), the pituitary hormone that normally triggers cortisol release. The US National Institutes of Health's PubChem database lists the compound under the name ACTH (4-7), Pro-Gly-Pro-, with the molecular formula C37H51N9O10S^[2]. Researchers extended the ACTH(4-7) fragment with a Pro-Gly-Pro tail to slow its breakdown in the body, and multiple papers describe the resulting molecule as an ACTH(4-10) analogue studied for nootropic (cognition-related) and neuroprotective effects, not for ACTH's original hormonal role^[3].

Why the nasal route, and not a pill

Like most peptides, Semax would be broken down by digestive enzymes if swallowed, which is one reason almost no therapeutic peptide reaches patients as an ordinary tablet. Russian researchers tested the intranasal route specifically to see whether Semax could act on the brain without an injection, and one of the foundational mechanism papers measured that question directly. Applied intranasally, Semax raised brain-derived neurotrophic factor (BDNF, a growth-and-survival signaling protein for neurons) in the basal forebrain of rats within three hours of dosing^[4]. That is evidence the nasal route can carry the peptide into brain tissue in animals. It says nothing about human nasal pharmacokinetics, appropriate dosing, or how any specific spray formulation behaves, and the published literature does not answer those questions for people.

What the studies show, and what they don't

The most substantial human data comes from Russian stroke-recovery research rather than studies of everyday cognition. A 2018 paper followed 110 patients at different stages of ischemic stroke and reported that intranasal Semax, alongside rehabilitation, raised BDNF plasma levels and tracked with faster functional recovery^[5]. Separately, rodent work found that Semax increased serotonin turnover in the striatum and amplified dopamine release when combined with amphetamine, changes in brain chemistry outside the melanocortin pathway most people associate with ACTH^[3].

Two things run through nearly all of this evidence. It comes from a small number of Russian research groups, and it is published mostly in Russian-language journals rather than the multi-center, English-language trial registries that back most Western drug approvals. A 2026 review of peptide therapeutics in aging medicine grouped Semax among the peptides that have not cleared that bar, distinguishing it from a smaller set of peptides in the same review that already carry FDA approval^[6]. None of that makes the Russian findings wrong. It means Semax has not produced the kind of independent, randomized, English-language trial evidence that regulators outside Russia require before licensing a drug.

Where the regulatory status actually stands

In Russia, Semax is a registered prescription nasal-spray medicine for indications including stroke recovery and cognitive impairment. That registration carries no legal weight outside Russia. The FDA has not approved Semax as a drug for any use, and the closest the agency has come to formally addressing it is procedural: its Pharmacy Compounding Advisory Committee discussed Semax-related bulk substances, Semax free base and Semax acetate, at a meeting held on 23 and 24 July 2026, evaluating them for possible inclusion on the section 503A list that governs what compounding pharmacies may legally prepare, for proposed uses in cerebral ischemia, migraine, and trigeminal neuralgia^[1]. Inclusion on that list, if it happens, would only make Semax eligible for pharmacy compounding under specific rules. It would not be an approval of Semax as a safe and effective drug, and no such approval exists in the US or the EU as of this writing.

Everything sold online outside Russia as 'research' Semax sits in that same unapproved category, in the same kind of grey-market channel that supplies other unlicensed peptides like BPC-157 and ipamorelin, with no batch-level quality control and no regulator confirming what is actually in the vial.

What we don't yet know

No completed Western-style randomized, placebo-controlled trial of Semax exists for any indication. Human pharmacokinetic data is limited to the specific registered Russian product used in the stroke studies, with nothing published on the vials sold as research chemicals elsewhere. And the long-term safety profile outside Russia's own post-marketing record has not been characterized. This article is educational and is not medical advice, and it does not describe how to prepare, dose, or administer Semax in any form. Anyone considering it should talk to a clinician who knows their medical history, not a forum thread.